JPWO2020084344A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020084344A5 JPWO2020084344A5 JP2021547960A JP2021547960A JPWO2020084344A5 JP WO2020084344 A5 JPWO2020084344 A5 JP WO2020084344A5 JP 2021547960 A JP2021547960 A JP 2021547960A JP 2021547960 A JP2021547960 A JP 2021547960A JP WO2020084344 A5 JPWO2020084344 A5 JP WO2020084344A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- composition
- pharmaceutical composition
- subject
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims description 72
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 14
- 206010016654 Fibrosis Diseases 0.000 claims description 12
- 230000004761 fibrosis Effects 0.000 claims description 12
- 230000014509 gene expression Effects 0.000 claims description 12
- 150000001413 amino acids Chemical class 0.000 claims description 10
- 210000004027 cells Anatomy 0.000 claims description 10
- 230000003247 decreasing Effects 0.000 claims description 9
- 101700012842 SMAD2 Proteins 0.000 claims description 8
- 102100017669 SMAD2 Human genes 0.000 claims description 8
- 210000004024 hepatic stellate cells Anatomy 0.000 claims description 8
- 201000009794 idiopathic pulmonary fibrosis Diseases 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 108010035532 Collagen Proteins 0.000 claims description 6
- 102000008186 Collagen Human genes 0.000 claims description 6
- 101710028471 MFGE8 Proteins 0.000 claims description 6
- 102100006993 MFGE8 Human genes 0.000 claims description 6
- 102100004961 MMP12 Human genes 0.000 claims description 6
- 108090000028 MMP12 Proteins 0.000 claims description 6
- 102100014894 MMP2 Human genes 0.000 claims description 6
- 101700060512 MMP2 Proteins 0.000 claims description 6
- 210000002540 Macrophages Anatomy 0.000 claims description 6
- 206010053219 Non-alcoholic steatohepatitis Diseases 0.000 claims description 6
- 229920001436 collagen Polymers 0.000 claims description 6
- 229960005188 collagen Drugs 0.000 claims description 6
- 206010001897 Alzheimer's disease Diseases 0.000 claims description 5
- 208000010125 Myocardial Infarction Diseases 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 230000035772 mutation Effects 0.000 claims description 5
- 102100017796 APP Human genes 0.000 claims description 4
- 108060000460 APP Proteins 0.000 claims description 4
- 101710038309 COL1A1 Proteins 0.000 claims description 4
- 101700033006 EGF Proteins 0.000 claims description 4
- 102100010813 EGF Human genes 0.000 claims description 4
- 229940116977 Epidermal Growth Factor Drugs 0.000 claims description 4
- 102000001389 Glial Fibrillary Acidic Protein Human genes 0.000 claims description 4
- 108010093505 Glial Fibrillary Acidic Protein Proteins 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- 101700021626 NAG4 Proteins 0.000 claims description 4
- 101700070190 PER2 Proteins 0.000 claims description 4
- 239000000090 biomarker Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 230000035755 proliferation Effects 0.000 claims description 4
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 4
- 208000005069 Pulmonary Fibrosis Diseases 0.000 claims description 3
- 230000001154 acute Effects 0.000 claims description 3
- 230000001684 chronic Effects 0.000 claims description 3
- 201000004044 liver cirrhosis Diseases 0.000 claims description 3
- 101710026064 ACTA2 Proteins 0.000 claims description 2
- 208000000044 Amnesia Diseases 0.000 claims description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 2
- 102000002110 C2 domain Human genes 0.000 claims description 2
- 108050009459 C2 domain Proteins 0.000 claims description 2
- 101710038301 COL1A2 Proteins 0.000 claims description 2
- 102000020504 Collagenase family Human genes 0.000 claims description 2
- 108060005980 Collagenase family Proteins 0.000 claims description 2
- 101700024891 EPHB2 Proteins 0.000 claims description 2
- 230000036499 Half live Effects 0.000 claims description 2
- 102100012521 ITGB5 Human genes 0.000 claims description 2
- 102000018358 Immunoglobulins Human genes 0.000 claims description 2
- 108060003951 Immunoglobulins Proteins 0.000 claims description 2
- 102000008607 Integrin beta3 Human genes 0.000 claims description 2
- 108010020950 Integrin beta3 Proteins 0.000 claims description 2
- 241000235058 Komagataella pastoris Species 0.000 claims description 2
- 101700083887 MAPK1 Proteins 0.000 claims description 2
- 210000000274 Microglia Anatomy 0.000 claims description 2
- 108009000163 Notch Signaling Proteins 0.000 claims description 2
- 102100008812 PSEN1 Human genes 0.000 claims description 2
- 101710033350 PSEN1 Proteins 0.000 claims description 2
- 241000700159 Rattus Species 0.000 claims description 2
- 108091005711 TGF-beta receptors Proteins 0.000 claims description 2
- 102100014320 TGFB1 Human genes 0.000 claims description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N Tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 2
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 claims description 2
- 108010037805 Transforming growth factor beta-1 Proteins 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 210000003008 brain-resident macrophage Anatomy 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 229960002424 collagenase Drugs 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000005755 formation reaction Methods 0.000 claims description 2
- 230000004217 heart function Effects 0.000 claims description 2
- 108010021518 integrin beta5 Proteins 0.000 claims description 2
- 102000006495 integrins Human genes 0.000 claims description 2
- 108010044426 integrins Proteins 0.000 claims description 2
- 230000003993 interaction Effects 0.000 claims description 2
- 238000001361 intraarterial administration Methods 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 230000003959 neuroinflammation Effects 0.000 claims description 2
- 238000006366 phosphorylation reaction Methods 0.000 claims description 2
- 230000000865 phosphorylative Effects 0.000 claims description 2
- 238000004904 shortening Methods 0.000 claims description 2
- 230000011664 signaling Effects 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 210000001519 tissues Anatomy 0.000 claims description 2
- 230000002861 ventricular Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 18
- 210000004556 Brain Anatomy 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 210000001320 Hippocampus Anatomy 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
Description
本発明は、例えば以下の実施形態を包含する:
[実施形態1]上皮細胞増殖因子(EGF)様ドメイン、C1ドメイン、及び場合によりシグナルペプチドを含むMFG-E8ポリペプチドを含むポリペプチドであって、
(a)機能的C2ドメインを欠失している、及び/又は
(b)メディンポリペプチド又はその断片を欠失している、ポリペプチド。
[実施形態2](a)ポリペプチドが、MFG-E8ポリペプチドのアミノ酸226~335を含むC末端ドメイン内で少なくとも1、2、3、4、5、10、15、20、25、30、35、40、45、50、55、60、65、70、75、80、85、90、95、100、又は105個のアミノ酸を欠失しており、
(b)ポリペプチドが、MFG-E8ポリペプチドの少なくとも180、190、200、210、215、220、225、230、235、240、245、250、255、260、265、270、275、又は280個のアミノ酸を含み、
(c)ポリペプチドは、配列番号10又は配列番号12のアミノ酸1~225の少なくとも75%、80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%、又は100%を含み、及び/又は
(d)ポリペプチドが、配列番号10又は配列番号12のアミノ酸24~225の少なくとも75%、80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%、又は100%を含む、実施形態1に記載のポリペプチド。
[実施形態3]異種配列をさらに含み、場合により異種配列は、FLAGタグ、HISタグ、及び/又は免疫グロブリンのFc部分を含む、実施形態1又は2に記載のポリペプチド。
[実施形態4]異種配列が、インビボでポリペプチドの半減期を増加させる、実施形態3に記載のポリペプチド。
[実施形態5]ポリペプチドがグリコシル化されていない、実施形態1~4のいずれかに記載のポリペプチド。
[実施形態6]ポリペプチドが、
(a)TGF-β1の発現レベルを減少させることができる、
(b)TGF-βシグナル伝達を減少させることができる、
(c)SMAD2及び/又はERKのリン酸化を減少させることができる、
(d)NOTCHシグナル伝達を増加させることができる、
(e)線維症関連遺伝子発現を減少させることができ、場合により線維症関連遺伝子がCol1a1、Col1a2、及び/又はActa2を含む、
(f)TGF-β受容体1(TGFBR1)と1つ以上のインテグリンの間の相互作用を減少させることができ、場合によりインテグリンはインテグリンβ3及び/又はインテグリンβ5を含む、
(g)肝星細胞(HSC)の増殖を減少させることができる、
(h)マトリックスメタロペプチダーゼ2(MMP2)、マトリックスメタロペプチダーゼ12(MMP12)、TMP2、ERK、SMAD2の発現レベルを減少させることができる、
(i)コラゲナーゼ活性を増加させることができる、及び/又は
(j)マクロファージによるコラーゲン取り込みを増加させることができる、実施形態1~5のいずれかに記載のポリペプチド。
[実施形態7]実施形態1~6のいずれかに記載のポリペプチド、並びに1つ以上の薬学的に許容される担体及び/又は希釈剤を含む医薬組成物。
[実施形態8]実施形態1~6のいずれかに記載のポリペプチドをコードする単離された核酸分子。
[実施形態9]核酸分子が、
(i)配列番号9又は配列番号11のヌクレオチド61~735、及び/又は
(ii)配列番号9又は列番号11のヌクレオチド130~735
に対して、少なくとも70%、75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%、又は100%の配列同一性を有する、実施形態8に記載の核酸分子。
[実施形態10]実施形態8又は9に記載の核酸分子を含むベクターであって、場合により発現ベクターである、ベクター。
[実施形態11]実施形態10に記載のベクターを含む宿主細胞。
[実施形態12]宿主細胞がピキア・パストリス(Pichia pastoris)である、実施形態11に記載の宿主細胞。
[実施形態13]ポリペプチドの製造方法であって、培地中で実施形態11又は12に記載の宿主細胞を培養して、ポリペプチドを製造する工程を含む、方法。
[実施形態14]マクロファージの活性を増加させる方法であって、マクロファージを実施形態1~6のいずれかに記載のポリペプチドと接触させる工程を含み、場合により活性はコラーゲン又は線維組織の取り込みを含む、方法。
[実施形態15]HSCを実施形態1~6のいずれかに記載のポリペプチドと接触させる工程を含む、HSCの増殖を減少させる又は阻害する方法。
[実施形態16]対象の細胞を実施形態1~6のいずれかに記載のポリペプチドと接触させる工程を含む、対象における線維症を減少させる又は阻害する方法。
[実施形態17]対象の細胞を実施形態1~6のいずれかに記載のポリペプチドと接触させる工程を含む、対象における脂肪症を減少させる又は阻害する方法。
[実施形態18]実施形態1~6のいずれかに記載のポリペプチドを対象に投与することを含む、それを必要とする対象における障害を治療又は予防する方法。
[実施形態19]障害が、線維症(慢性又は急性)、肝硬変、脂肪症、非アルコール性脂肪性肝炎(NASH)、及び/又は肺線維症である、実施形態18に記載の方法。
[実施形態20]障害が特発性肺線維症(IPF)である、実施形態18に記載の方法。
[実施形態21]ポリペプチドがIPFバイオマーカーの発現レベルを改変させ、場合により、ポリペプチドが、αSMA、コラーゲン(Col1a1)、TMP2、MMP2、MMP12、リン酸化ERK、ERK、リン酸化SMAD2、及びSMAD2から選択される少なくとも1つのバイオマーカーの発現レベルを減少させる、実施形態20に記載の方法。
[実施形態22]障害が心筋梗塞である、実施形態18に記載の方法。
[実施形態23]ポリペプチドが、心臓の機能を増加させ、場合により、ポリペプチドが、左室駆出率及び/又は内径短縮率を増加させる、実施形態22に記載の方法。
[実施形態24]ポリペプチドが、心筋梗塞に関連する線維症を阻害する又は減少させる、実施形態22又は23に記載の方法。
[実施形態25]障害がアルツハイマー病である、実施形態18に記載の方法。
[実施形態26]対象が、(i)K670N/M671L、I716V、及びV717Iから選択されるアミロイド前駆体タンパク質(APP)における少なくとも1つの突然変異、並びに/又は(ii)M146L及びL286Vから選択されるPSEN1における少なくとも1つの突然変異を有する、実施形態25に記載の方法。
[実施形態27]ポリペプチドが、アルツハイマー病に関連する記憶喪失及び/又は行動を改善する、実施形態25又は26に記載の方法。
[実施形態28]ポリペプチドが、対象の脳、場合により対象の海馬及び/又は脳皮質において、
(i)アミロイド斑の量、
(ii)アミロイドベータの量、
(iii)ミクログリアの数、
(iv)神経炎症、及び/又は
(v)グリア線維性酸性タンパク質(GFAP)の量
を減少させる、実施形態25、26又は27に記載の方法。
[実施形態29]ポリペプチドが、静脈内、皮下、動脈内、腹腔内、又は筋肉内経路を介して投与される、実施形態16~28のいずれかに記載の方法。
[実施形態30]対象が哺乳動物であり、場合により、哺乳動物がヒト、マウス、又はラットである、実施形態16~29のいずれかに記載の方法。
[実施形態31]障害を治療する追加の薬剤を対象に投与することをさらに含む、実施形態16~30のいずれかに記載の方法。
[実施形態32]方法が対象においてアミロイド形成を誘導しない、実施形態16~31のいずれかに記載の方法。
[実施形態33]実施形態1~6のいずれかに記載のポリペプチドを含むキット。
以下の実施例は、限定としてではなく、例示として提供される。
The invention includes, for example, the following embodiments:
[Embodiment 1] A polypeptide comprising an MFG-E8 polypeptide comprising an epidermal growth factor (EGF)-like domain, a C1 domain, and optionally a signal peptide,
(a) lacking a functional C2 domain and/or
(b) a polypeptide lacking a medin polypeptide or fragment thereof;
[Embodiment 2] (a) the polypeptide comprises at least 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, within the C-terminal domain comprising amino acids 226-335 of the MFG-E8 polypeptide; is missing 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, or 105 amino acids;
(b) the polypeptide is at least 180, 190, 200, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275, or 280 of the MFG-E8 polypeptide containing amino acids,
(c) the polypeptide is at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92% of amino acids 1-225 of SEQ ID NO: 10 or SEQ ID NO: 12 , 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, and/or
(d) the polypeptide is at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92% of amino acids 24-225 of SEQ ID NO:10 or SEQ ID NO:12 , 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%.
[Embodiment 3] A polypeptide according to embodiment 1 or 2, further comprising a heterologous sequence, optionally wherein the heterologous sequence comprises a FLAG tag, a HIS tag and/or the Fc portion of an immunoglobulin.
[Embodiment 4] The polypeptide of embodiment 3, wherein the heterologous sequence increases the half-life of the polypeptide in vivo.
[Embodiment 5] The polypeptide of any of embodiments 1-4, wherein the polypeptide is non-glycosylated.
[Embodiment 6] The polypeptide is
(a) capable of decreasing the expression level of TGF-β1;
(b) capable of decreasing TGF-β signaling;
(c) capable of decreasing phosphorylation of SMAD2 and/or ERK;
(d) can increase NOTCH signaling,
(e) capable of decreasing fibrosis-associated gene expression, optionally wherein the fibrosis-associated gene comprises Col1a1, Col1a2, and/or Acta2;
(f) can decrease the interaction between TGF-beta receptor 1 (TGFBR1) and one or more integrins, optionally including integrin β3 and/or integrin β5;
(g) capable of reducing the proliferation of hepatic stellate cells (HSCs);
(h) can reduce the expression levels of matrix metallopeptidase 2 (MMP2), matrix metallopeptidase 12 (MMP12), TMP2, ERK, SMAD2;
(i) can increase collagenase activity, and/or
(j) The polypeptide of any of embodiments 1-5, which is capable of increasing collagen uptake by macrophages.
[Embodiment 7] A pharmaceutical composition comprising the polypeptide of any of embodiments 1-6 and one or more pharmaceutically acceptable carriers and/or diluents.
[Embodiment 8] An isolated nucleic acid molecule encoding a polypeptide according to any of embodiments 1-6.
[Embodiment 9] The nucleic acid molecule is
(i) nucleotides 61-735 of SEQ ID NO:9 or SEQ ID NO:11, and/or
(ii) nucleotides 130-735 of SEQ ID NO:9 or SEQ ID NO:11
at least 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 9. The nucleic acid molecule of embodiment 8, having 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity.
[Embodiment 10] A vector comprising the nucleic acid molecule of embodiment 8 or 9, optionally an expression vector.
[Embodiment 11] A host cell containing the vector of Embodiment 10.
[Embodiment 12] The host cell according to embodiment 11, wherein the host cell is Pichia pastoris.
[Embodiment 13] A method for producing a polypeptide, comprising the step of culturing the host cell of embodiment 11 or 12 in a medium to produce the polypeptide.
[Embodiment 14] A method of increasing the activity of macrophages comprising contacting macrophages with a polypeptide of any of embodiments 1-6, wherein optionally the activity comprises uptake of collagen or fibrous tissue ,Method.
[Embodiment 15] A method of reducing or inhibiting proliferation of HSCs comprising contacting HSCs with a polypeptide according to any of embodiments 1-6.
[Embodiment 16] A method of reducing or inhibiting fibrosis in a subject comprising contacting a cell of the subject with a polypeptide of any of embodiments 1-6.
[Embodiment 17] A method of reducing or inhibiting adiposity in a subject comprising contacting a cell of the subject with a polypeptide of any of embodiments 1-6.
[Embodiment 18] A method of treating or preventing a disorder in a subject in need thereof, comprising administering the polypeptide of any of embodiments 1-6 to the subject.
[Embodiment 19] The method of embodiment 18, wherein the disorder is fibrosis (chronic or acute), cirrhosis, steatosis, non-alcoholic steatohepatitis (NASH), and/or pulmonary fibrosis.
[Embodiment 20] The method of embodiment 18, wherein the disorder is idiopathic pulmonary fibrosis (IPF).
[Embodiment 21] The polypeptide alters the expression level of an IPF biomarker, optionally wherein the polypeptide is αSMA, collagen (Col1a1), TMP2, MMP2, MMP12, phosphorylated ERK, ERK, phosphorylated SMAD2, and SMAD2 21. The method of embodiment 20, wherein the expression level of at least one biomarker selected from is decreased.
[Embodiment 22] The method of embodiment 18, wherein the disorder is myocardial infarction.
[Embodiment 23] The method of embodiment 22, wherein the polypeptide increases cardiac function, optionally the polypeptide increases left ventricular ejection fraction and/or caliber shortening fraction.
[Embodiment 24] A method according to embodiment 22 or 23, wherein the polypeptide inhibits or reduces fibrosis associated with myocardial infarction.
[Embodiment 25] The method of embodiment 18, wherein the disorder is Alzheimer's disease.
[Embodiment 26] The subject is selected from (i) at least one mutation in amyloid precursor protein (APP) selected from K670N/M671L, I716V, and V717I, and/or (ii) M146L and L286V 26. The method of embodiment 25, having at least one mutation in PSEN1.
[Embodiment 27] A method according to embodiment 25 or 26, wherein the polypeptide ameliorates memory loss and/or behavior associated with Alzheimer's disease.
[Embodiment 28] The polypeptide is
(i) amount of amyloid plaques;
(ii) the amount of amyloid beta;
(iii) the number of microglia;
(iv) neuroinflammation, and/or
(v) amount of glial fibrillary acidic protein (GFAP)
28. The method of embodiment 25, 26 or 27, wherein the
[Embodiment 29] The method of any of embodiments 16-28, wherein the polypeptide is administered via an intravenous, subcutaneous, intraarterial, intraperitoneal, or intramuscular route.
[Embodiment 30] The method of any of embodiments 16-29, wherein the subject is a mammal, optionally the mammal is a human, mouse, or rat.
Embodiment 31 The method of any of Embodiments 16-30, further comprising administering to the subject an additional agent that treats the disorder.
[Embodiment 32] The method of any of Embodiments 16-31, wherein the method does not induce amyloid formation in the subject.
[Embodiment 33] A kit comprising the polypeptide of any of embodiments 1-6.
The following examples are provided by way of illustration and not by way of limitation.
Claims (36)
(a)機能的C2ドメインを欠失している、及び/又は
(b)メディンポリペプチド又はその断片を欠失している、ポリペプチド。 A polypeptide comprising an MFG-E8 polypeptide comprising an epidermal growth factor (EGF)-like domain, a C1 domain, and optionally a signal peptide,
(a) lacking a functional C2 domain and/or
(b) a polypeptide lacking a medin polypeptide or fragment thereof;
(b)ポリペプチドが、MFG-E8ポリペプチドの少なくとも180、190、200、210、215、220、225、230、235、240、245、250、255、260、265、270、275、又は280個のアミノ酸を含み、
(c)ポリペプチドは、配列番号10又は配列番号12のアミノ酸1~225の少なくとも75%、80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%、又は100%を含み、及び/又は
(d)ポリペプチドが、配列番号10又は配列番号12のアミノ酸24~225の少なくとも75%、80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%、又は100%を含む、請求項1に記載のポリペプチド。 (a) the polypeptide is at least 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45 within the C-terminal domain comprising amino acids 226-335 of the MFG-E8 polypeptide; , 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, or 105 amino acids deleted;
(b) the polypeptide is at least 180, 190, 200, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275, or 280 of the MFG-E8 polypeptide containing amino acids,
(c) the polypeptide is at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92% of amino acids 1-225 of SEQ ID NO: 10 or SEQ ID NO: 12 , 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, and/or
(d) the polypeptide is at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92% of amino acids 24-225 of SEQ ID NO:10 or SEQ ID NO:12 , 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%.
(a)TGF-β1の発現レベルを減少させることができる、
(b)TGF-βシグナル伝達を減少させることができる、
(c)SMAD2及び/又はERKのリン酸化を減少させることができる、
(d)NOTCHシグナル伝達を増加させることができる、
(e)線維症関連遺伝子発現を減少させることができ、場合により線維症関連遺伝子がCol1a1、Col1a2、及び/又はActa2を含む、
(f)TGF-β受容体1(TGFBR1)と1つ以上のインテグリンの間の相互作用を減少させることができ、場合によりインテグリンはインテグリンβ3及び/又はインテグリンβ5を含む、
(g)肝星細胞(HSC)の増殖を減少させることができる、
(h)マトリックスメタロペプチダーゼ2(MMP2)、マトリックスメタロペプチダーゼ12(MMP12)、TMP2、ERK、SMAD2の発現レベルを減少させることができる、
(i)コラゲナーゼ活性を増加させることができる、及び/又は
(j)マクロファージによるコラーゲン取り込みを増加させることができる、請求項1~5のいずれか一項に記載のポリペプチド。 the polypeptide is
(a) capable of decreasing the expression level of TGF-β1;
(b) capable of decreasing TGF-β signaling;
(c) capable of decreasing phosphorylation of SMAD2 and/or ERK;
(d) can increase NOTCH signaling,
(e) capable of decreasing fibrosis-associated gene expression, optionally wherein the fibrosis-associated gene comprises Col1a1, Col1a2, and/or Acta2;
(f) can decrease the interaction between TGF-beta receptor 1 (TGFBR1) and one or more integrins, optionally including integrin β3 and/or integrin β5;
(g) capable of reducing the proliferation of hepatic stellate cells (HSCs);
(h) can reduce the expression levels of matrix metallopeptidase 2 (MMP2), matrix metallopeptidase 12 (MMP12), TMP2, ERK, SMAD2;
(i) can increase collagenase activity, and/or
(j) The polypeptide of any one of claims 1-5, which is capable of increasing collagen uptake by macrophages.
(i)配列番号9又は配列番号11のヌクレオチド61~735、及び/又は
(ii)配列番号9又は列番号11のヌクレオチド130~735
に対して、少なくとも70%、75%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%、又は100%の配列同一性を有する、請求項8に記載の核酸分子。 the nucleic acid molecule
(i) nucleotides 61-735 of SEQ ID NO:9 or SEQ ID NO:11, and/or
(ii) nucleotides 130-735 of SEQ ID NO:9 or SEQ ID NO:11
at least 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 9. The nucleic acid molecule of claim 8, having 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity.
(i)アミロイド斑の量、
(ii)アミロイドベータの量、
(iii)ミクログリアの数、
(iv)神経炎症、及び/又は
(v)グリア線維性酸性タンパク質(GFAP)の量
を減少させる、請求項25~27のいずれか一項に記載の組成物。 wherein the polypeptide or pharmaceutical composition is in the subject's brain, optionally in the subject's hippocampus and/or brain cortex,
(i) amount of amyloid plaques;
(ii) the amount of amyloid beta;
(iii) the number of microglia;
(iv) neuroinflammation, and/or
28. The composition of any one of claims 25-27 , wherein (v) the amount of glial fibrillary acidic protein (GFAP) is reduced.
A kit comprising a polypeptide according to any one of claims 1-6 or a pharmaceutical composition according to claim 7 .
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180128204A KR102129179B1 (en) | 2018-10-25 | 2018-10-25 | Composition for alzheimer's disease treatment or prevention containing recombinant protein for alzheimer's disease treatment or prevention |
KR10-2018-0128033 | 2018-10-25 | ||
KR1020180128033A KR102129178B1 (en) | 2018-10-25 | 2018-10-25 | Composition for myocardial infarction treatment or prevention containing recombinant protein for myocardial infarction treatment or prevention |
KR10-2018-0128204 | 2018-10-25 | ||
KR1020180128625A KR102161892B1 (en) | 2018-10-26 | 2018-10-26 | Composition for idiopathic pulmonary fibrosis treatment or prevention containing recombinant protein for idiopathic pulmonary fibrosis treatment or prevention |
KR10-2018-0128625 | 2018-10-26 | ||
PCT/IB2019/001136 WO2020084344A2 (en) | 2018-10-25 | 2019-10-24 | Compositions and methods for treating or preventing fibrosis |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022509445A JP2022509445A (en) | 2022-01-20 |
JPWO2020084344A5 true JPWO2020084344A5 (en) | 2022-10-27 |
Family
ID=70331794
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021547960A Pending JP2022509445A (en) | 2018-10-25 | 2019-10-24 | Compositions and Methods for Treating or Preventing Fibrosis |
Country Status (5)
Country | Link |
---|---|
US (1) | US20210388041A1 (en) |
EP (1) | EP3870210A4 (en) |
JP (1) | JP2022509445A (en) |
CN (1) | CN113301914A (en) |
WO (1) | WO2020084344A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202122414A (en) | 2019-09-06 | 2021-06-16 | 瑞士商諾華公司 | Therapeutic Fusion Proteins |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1004664A1 (en) * | 1998-11-24 | 2000-05-31 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Compositions and methods using lactadherin or variants thereof |
JP4160292B2 (en) * | 2001-11-20 | 2008-10-01 | 独立行政法人科学技術振興機構 | Promoter and inhibitor for removal of apoptotic cells in vivo |
US10005838B2 (en) * | 2013-07-19 | 2018-06-26 | The Regents Of The University Of California | Milk fat globule epidermal growth factor 8 regulates fatty acid uptake |
WO2015025956A1 (en) * | 2013-08-22 | 2015-02-26 | 国立大学法人九州大学 | Pharmaceutical composition for treating myocardial damage, pharmaceutical composition for preventing myocardial damage, pharmaceutical composition for treating heart failure, pharmaceutical composition for preventing heart failure, method for treating or preventing myocardial damage or heart failure, mfg-e8, uses of mfg-e8, and method for screening compounds for treating or preventing myocardial damage or heart failure |
KR20170013621A (en) * | 2015-07-28 | 2017-02-07 | (주) 넥셀 | Composition for preventing or treating tissue fibrosis by using milk fat globule-EGF factor 8 |
-
2019
- 2019-10-24 US US17/285,040 patent/US20210388041A1/en active Pending
- 2019-10-24 WO PCT/IB2019/001136 patent/WO2020084344A2/en unknown
- 2019-10-24 EP EP19875681.9A patent/EP3870210A4/en active Pending
- 2019-10-24 CN CN201980086450.8A patent/CN113301914A/en active Pending
- 2019-10-24 JP JP2021547960A patent/JP2022509445A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7045302B2 (en) | Expressed ligand-vascular intercellular signaling molecule | |
US6689580B1 (en) | Growth factor | |
JP3017962B2 (en) | Method for producing pharmaceutical composition for increasing hematocrit | |
US9056892B2 (en) | Retrograde transport peptide and use of same for delivery to central nervous system | |
EP1549679B1 (en) | Fusion protein comprising angiopoietin receptor-binding and a multimerization domain | |
JP2023025005A (en) | Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases | |
CN113316639A (en) | Treatment of gonadal-associated viruses for the treatment of pompe disease | |
CA2529179A1 (en) | Recombinant adeno-associated virus vector for treatment of alzheimer disease | |
CA2145778A1 (en) | Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids | |
AU2003287243A1 (en) | Cell-based vegf delivery | |
JPH11509187A (en) | Regulation of endothelial cell proliferation | |
US10729789B2 (en) | Compositions and methods for adeno-associated virus mediated gene expression in myofibroblast-like cells | |
DK167814B1 (en) | AMERICAN AMERICAN AMERICAN, HUMAN CALCITONIN GENERATED PEPTIME, PREPARATIONS FOR THE PREPARATION OF ANY SEPTEMBLY, AND THE VECTOR | |
AU2016319540A1 (en) | Novel human serum albumin mutant | |
JP2004099471A (en) | Medicine for treating cardiac infarction and cardiac failure | |
JP3903503B2 (en) | Soluble polypeptide | |
JPWO2020084344A5 (en) | ||
US7507712B2 (en) | NOV protein: an anti-angiogenic agent and its use, in particular for the treatment of cancer | |
JPH10262668A (en) | Dna sequence including protein-encoded sequence that coding for angiogenesis factor | |
KR102460983B1 (en) | Camkk1 as a novel regenerative therapeutic | |
JPH05103666A (en) | Method for manifesting human nerve growth factor | |
Chou et al. | Characterization of pregnancy-specific β1-glycoprotein synthesized by human placental fibroblasts | |
WO2023171577A1 (en) | Neuronal migration promoter, and use thereof | |
WO2002089727A2 (en) | Methods of using cytokine c17 | |
Smagur et al. | Recombinant angioarrestin secreted from mouse melanoma cells inhibits growth of primary tumours |